Advertisement
 
YOU ARE HERE: LAT HomeCollectionsNaglazyme Drug
IN THE NEWS

Naglazyme Drug

MORE STORIES ABOUT:
FEATURED ARTICLES
BUSINESS
June 2, 2005 | From Bloomberg News
BioMarin Pharmaceutical Inc. said the Food and Drug Administration approved marketing of a therapy against a rare fatal genetic disorder. The company expects to receive the European Commission's opinion on the treatment, known as Naglazyme, in the fourth quarter, Novato, Calif.-based BioMarin said. If the opinion is positive, final approval from the European regulator is expected in early 2006, it said.
ARTICLES BY DATE
BUSINESS
June 2, 2005 | From Bloomberg News
BioMarin Pharmaceutical Inc. said the Food and Drug Administration approved marketing of a therapy against a rare fatal genetic disorder. The company expects to receive the European Commission's opinion on the treatment, known as Naglazyme, in the fourth quarter, Novato, Calif.-based BioMarin said. If the opinion is positive, final approval from the European regulator is expected in early 2006, it said.
Los Angeles Times Articles
|